Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxipurinol - XORTX Therapeutics

Next Previous
Drug Profile

Oxipurinol - XORTX Therapeutics

Alternative Names: Oxypurinol - XORTX; XORLO; XRx 101; XRx-008; XRx-026

Latest Information Update: 09 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XORTX Pharma
  • Developer XORTX Therapeutics
  • Class Anti-ischaemics; Antigouts; Antivirals; Pyrazoles; Pyrimidines; Small molecules; Urologics
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autosomal dominant polycystic kidney disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Gout
  • Phase II/III Autosomal dominant polycystic kidney disease
  • Phase II Acute kidney injury; Acute lung injury

Most Recent Events

  • 03 Sep 2025 XORTX Therapeutics anticipates submission of the IND for Gout in the second half of 2025
  • 07 Aug 2025 XORTX Therapeutics plans to engage with EMA to define the regulatory path for Oxipurinol approval in European Union
  • 07 Aug 2025 XORTX Therapeutics plans to submit IND application to US FDA incorporating novel formulation data

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top